Similarly, the therapeutic efficacy of the IDH inhibitors (NTC02428855; NTC02989857; NTC02381886) is currently being tested for patients with IDH-mutant iCCA and, in parallel, targeting NTRK fusions with larotrectinib [139] or entrectinib [140] have shown promising results for the treatment of previously treated advanced solid tumors, including also CCA. This evidence concerns the gene IDH2 and cholangiocarcinoma.